AUA Released Joint Guidelines on Stress Urinary Incontinence


American Urological Association  pic

American Urological Association

A physician and pharmaceutical researcher, Dr. Erol Onel serves as the vice president of Heron Therapeutics, Inc. In this capacity, he works with a team of professionals as they seek approval for a long-acting non-opioid drug. Over the years, Dr. Erol Onel has belonged to several professional organizations, including the American Urological Association (AUA).

Dedicated to improving urologic care through research, policy, and education, the AUA recently released new joint clinical guidelines for the treatment of stress urinary incontinence (SUI). This condition affects nearly 50 percent of women in the United States and is signified by involuntary urine leakage due to sneezing, laughing, or other activities that increase abdominal pressure. In many cases, women opt for surgical treatment of SUI symptoms.

The AUA wrote the joint evidence-based guidelines for surgical treatment with the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU). They include a total of 24 treatment recommendations, including alternatives to various surgical options and information about determining when additional evaluations are needed to confirm SUI. A panel of SUI experts worked on creating the clinical guideline, and it was subject to 93 peer reviews before being approved and released by the AUA and SUFU.

How Non-Opioid Drugs Work on Pain

Erol Onel pic

Erol Onel

As vice president at Heron Therapeutics in La Jolla, California, Dr. Erol Onel directs the company’s pain franchise. Currently in leadership of a team charged with approval of a new non-opioid drug, Dr. Erol Onel works on a national and global level.

For patients with pain, non-opioid analgesics and anti-inflammatory drugs can help to interrupt the pain signal process. Unlike opioids, they usually do not work directly on the central nervous system, but rather act at the peripheral level.

Non-steroidal anti-inflammatory drugs (NSAIDs) block the COX-1 and COX-2 enzymes that are key players in the pain process. NSAIDs reduce the sensation of pain as well as inflammation.